Scope
ASH’s final 2026 guideline addresses frontline acute lymphoblastic leukaemia in adolescents and young adults, including selected T-lymphoblastic lymphoma decisions. It favours paediatric-inspired treatment while separating subtype-specific therapy, asparaginase safety, CNS prophylaxis and response-adapted treatment. Many recommendations have very-low-certainty evidence, so the distinction between a conditional option and an evidence gap matters.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Population and initial treatment approach
- The guideline concerns adolescents and young adults; it cites the cancer age range of 15–39 years. Provide access, whenever feasible, to clinicians and institutions experienced in AYA ALL and its developmental needs. [1]
- For frontline B-ALL, T-ALL or T-lymphoblastic lymphoma in AYAs, ASH recommends paediatric-inspired, asparaginase-containing regimens (strong, moderate-certainty evidence). Subtype-specific treatment decisions, particularly Philadelphia-positive ALL, require the separate recommendations below. [1]
Asparaginase modification, monitoring and complications
- For AYAs receiving frontline paediatric-inspired ALL regimens, empiric PEG-asparaginase capping or dose reduction is a conditional toxicity-mitigation option (very low certainty), paired with therapeutic drug monitoring. The panel defines capping as a maximum 3750 IU; this is a strategy definition rather than a complete individual dosing protocol. [1]
- With frontline paediatric-inspired ALL treatment in AYAs, use prophylactic premedication against hypersensitivity (strong recommendation, very low certainty): at least an intravenous steroid, with possible antihistamine and/or acetaminophen. Pair premedication with drug monitoring to detect antibody-mediated or silent inactivation. [1]
- For PEG-asparaginase monitoring during dose modification or premedication in AYA ALL, the panel recommends activity at least 0.1 IU/mL for at least 14 days to ensure depletion. Monitoring timing and targets vary across studies; these recommendations concern PEG-asparaginase, not calaspargase pegol. [1]
- Do not routinely replace fibrinogen with cryoprecipitate or fibrinogen concentrate outside active bleeding in AYAs on frontline asparaginase-containing ALL regimens (strong recommendation, very low certainty). [1]
- Do not routinely use unfractionated heparin for VTE prophylaxis during frontline asparaginase-containing ALL treatment in AYAs (strong recommendation, very low certainty). Evidence is insufficient to recommend for or against routine low-molecular-weight heparin, direct oral anticoagulants or antithrombin replacement. [1]
- If an AYA develops PEG-asparaginase allergy or hypersensitivity during frontline ALL therapy, switch to an Erwinia-based formulation rather than discontinue asparaginase (strong recommendation, very low certainty). The panel could not recommend desensitisation because comparative evidence was lacking. [1]
- For nonhypersensitivity asparaginase toxicity during frontline AYA ALL therapy, evidence is insufficient for a recommendation on restarting treatment. Use the applicable toxicity protocol and product guidance; the guideline does not provide a universal rechallenge rule. [1]
First remission, MRD and transplantation
- ASH conditionally advises against routine allogeneic transplantation as consolidation in first complete remission for AYA ALL (very low certainty). Persistent MRD, induction failure or high-risk biology may justify transplant; Philadelphia-positive ALL is addressed separately, so this is not a blanket rule against transplantation. [1]
- Measure MRD response as standard care in AYA ALL. Persistent MRD after at least 3 months of frontline treatment, comprising induction and at least 1 postremission block, warrants changing treatment (strong recommendation, very low certainty). Immunotherapy and/or transplantation are possible approaches, but optimal sequencing is undefined. [1]
Subtype-specific additions and evidence gaps
- For CD20-positive B-ALL in AYAs receiving frontline therapy, conditionally add rituximab to standard chemotherapy (very low certainty). The minimum CD20 expression threshold and optimal dosing, frequency and timing remain uncertain. [1]
- For AYA B-ALL that reaches morphologic remission during frontline treatment, conditionally add blinatumomab regardless of MRD status (very low certainty). Evidence within conventional paediatric-inspired backbones remains limited. [1]
- For frontline B-ALL in AYAs, evidence is insufficient to recommend for or against adding inotuzumab ozogamicin. This is an evidence gap, rather than a recommendation to use or avoid it. [1]
- For AYA T-ALL receiving all planned asparaginase doses, including Capizzi-methotrexate interim maintenance, evidence is insufficient for or against nelarabine. For frontline T-lymphoblastic lymphoma, ASH conditionally advises against adding nelarabine because efficacy evidence is insufficient (very low certainty). [1]
- For frontline T-ALL in AYAs, conditionally avoid adding bortezomib (very low certainty). For T-lymphoblastic lymphoma, evidence is insufficient to recommend for or against it; these two populations should not be conflated. [1]
- For AYA Philadelphia-positive ALL, conditionally prefer reduced-intensity therapy plus a tyrosine kinase inhibitor for induction over intensive chemotherapy plus a TKI (very low certainty). Follow with postremission chemotherapy and/or immunotherapy plus a TKI; transplantation may consolidate first remission. Applicability to the youngest AYAs on paediatric-inspired regimens is less certain. [1]
CNS prophylaxis
- For frontline ALL in AYAs, either intrathecal methotrexate or triple intrathecal therapy is conditionally suggested for CNS prophylaxis (very low certainty). Philadelphia-positive ALL also requires concurrent intrathecal prophylaxis. [1]
- Do not routinely use cranial radiation for CNS prophylaxis in AYAs treated on a frontline paediatric-inspired, asparaginase-containing ALL backbone (conditional, very low certainty). Uncertainty remains for T-ALL when nelarabine cannot be given. [1]
Developmental, psychosocial and supportive care
- Routinely screen AYAs with ALL for depression, anxiety and other psychological problems, and provide multidisciplinary support. Assess social supports and provide care navigation, financial counselling and resources. [1]
- Discuss sexual health and identity from diagnosis through survivorship. Provide multidisciplinary fertility consultation before treatment whenever possible and continued support throughout treatment and survivorship. [1]
- Introduce palliative care early, regardless of disease status. Discuss goals and end-of-life concepts before crises, revisit them at transitions, and involve family or caregivers to the extent the AYA wishes. [1]
- Assess developmental needs and treatment goals and offer appropriate clinical trials. Where medically feasible, organise treatment flexibly around the individual’s developmental context. [1]
Limitations and use
- This summary covers the final published frontline AYA recommendations, not a complete chemotherapy protocol or guidance for older adults, young children or relapsed disease.
- Asparaginase management here concerns PEG-asparaginase; full formulation-specific dosing, toxicity management, monitoring schedules and prescribing safeguards require the original protocol and specialist team.
- Many questions rely on indirect or very-low-certainty evidence. Absence of a recommendation must not be interpreted as equivalence, proof of safety or a routine instruction to withhold treatment.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Acute lymphoblastic leukaemia in adolescents and young adults: frontline management
Selected recommendation material consulted
Publication details
- Issuing organisation
- ASH
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.